SCHEMBL20819210

SCHEMBL20819210

COC(=O)c1ccc2[nH]c(-n3[nH]c(CSc4nnc(C)s4)c(C)c3=O)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.49
▸ NPC1 O15118 5/20 0.49
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ RAB9A P51151 5/20 0.49
▸ MAPT P10636 4/20 0.49
▸ LMNA P02545 1/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ HPGD P15428 3/20 0.40
▸ ABL1 P00519 1/20 0.39
▸ RIN1 Q13671 1/20 0.39
▸ ALKBH3 Q96Q83 2/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ CYP2C19 P33261 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20830325 0.91 KDM4E (0.43) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL20830342 0.84 KDM4E (0.52) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL20830169 0.82 ABL1 (0.58) KDM4EABL1RIN1ALKBH3
SCHEMBL11188532 0.68 MAPT (1.00) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL20830289 0.68 ABL1 (0.58) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL20819197 0.66 ALKBH3 (0.62) NPC1SMN1; SMN2RAB9AKDM4EALKBH3
SCHEMBL5032566 0.64 HSP90AA1 (0.53) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL16938454 0.63 BRD4 (0.61) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
Hydrochloric Acid SCHEMBL7324036 0.63 HSP90AA1 (0.51) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL1170648 0.63 KDM4E (0.61) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof D. E. SHAW RESEARCH, LLC 2020-10-01 — — US disclosed
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof D. E. SHAW RESEARCH, LLC 2020-10-01 — — US disclosed
EP-3681499-A1 COMPOUNDS AS RAS INHIBITORS AND USE THEREOF D.E. Shaw Research, LLC (US) 2020-07-22 — — EP disclosed
WO-2019055540-A1 COMPOUNDS AS RAS INHIBITORS AND USE THEREOF D.E. SHAW RESEARCH, LLC (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof KRAS, NRAS, HRAS ALDH1A1 2215/4885NPC1 1256/4885SMN1; SMN2 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback